Search

The type of adjuvant systemic therapy has an impact on Edmonton Symptom Assessment System scores in patients with breast cancer, as reported in a recent retrospective analysis. Triple-negative tumor histology and the outcomes of previous neoadjuvant treatment were related to symptom burden. Multimodal treatment in breast cancer patients can have side effects, as reported in...

A randomized controlled trial found that nomograms based on multiple Cox regression models could effectively predict the risk factors associated with overall survival and cancer-specific survival in patients with localized prostate cancer as well as assess survival differences between surgery and radiotherapy.  Prostate cancer affects a substantial proportion of men across the globe, with more...

A newly published phase 2 study finds that the antitumor effect of AZD4635 with durvalumab or oleclumab is minimal in pretreated metastatic castration-resistant prostate cancer, with the treatment regimen being well-tolerated and generally safe. Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis and limited overall survival rates. The standard treatment for mCRPC patients comprises...

A nurse-led mobile-based health coaching program promoted positive lifestyle changes that improved various parameters of metabolic syndrome in prostate cancer patients. Prostate cancer patients are prone to adverse metabolic changes that stem from the physical effects of androgen deprivation therapy (ADT). These changes include body fat accumulation and abnormal fasting glucose levels, with subsequent development...

Results of a phase 2 study indicate that bipolar androgen therapy with nivolumab may augment the anti-tumor immunologic response of the body against metastatic castration-resistant prostate cancer, which is further strengthened by immune checkpoint inhibition. Bipolar androgen therapy (BAT) in metastatic castration-resistant prostate cancer (mCRPC) patients drives testosterone levels above the physiologic range and then...

A retrospective cohort study finds that multimodal radiomics and pathomics based on deep learning algorithms are useful tools for predicting the risk of bone metastases in patients diagnosed with primary prostate cancer. Bone metastasis is a common consequence of disease progression in primary prostate cancer patients and plays an important role in the morbidity and...

Secondary analysis of a prospective trial finds that while repeated screening for prostate cancer is crucial to the detection of pathology, the proportion of magnetic resonance imaging scans that prompt suspicion of cancer is relatively low. Prostate cancer screening with prostate-specific antigen (PSA) plays a pivotal role in decreasing cancer-related mortality. Screening with PSA testing...

Findings seen among poor surgical candidates, with recurrence risk of 10 percent seen at 16 months Cryoablation can be performed effectively in nonsurgical breast cancer patients with varying tumors, according to a study presented at the annual meeting of the Society of Interventional Radiology, held from March 23 to 28 in Salt Lake City. Jolie...

In a phase III study, the administration of pembrolizumab with chemotherapy provided progression-free survival and overall survival benefits with a satisfactory safety profile compared to placebo in previously untreated patients with metastatic squamous non-small-cell lung cancer. The KEYNOTE-407 phase III study assessed the long-term survival outcomes in metastatic squamous non-small-cell lung cancer (NSCLC) patients treated...

Trastuzumab deruxtecan demonstrated an acceptable safety profile and was associated with a clinically significant objective response rate in patients with HER2-mutant metastatic non-small-cell lung cancer in a phase II study. Human epidermal growth factor receptor (HER2) mutations are present in a small number of non-squamous non-small-cell lung cancer (NSCLC) patients. Trastuzumab deruxtecan (T-DXd) is approved...